Straits Times Index
3,330.77 -0.04 (-0.00%) Nikkei
38,683.93 -19.58 (-0.05%) Hang Seng
18,366.95 -109.85 (-0.59%) FTSE 100
8,245.37 -39.97 (-0.48%) Bitcoin USD
69,462.48 -1,299.84 (-1.84%) CMC Crypto 200
1,441.39 -37.31 (-2.52%)
APLS Oct 2024 45.000 put
| Previous close | 8.60 |
| Open | 8.50 |
| Bid | 8.20 |
| Ask | 9.30 |
| Strike | 45.00 |
| Expiry date | 2024-10-18 |
| Day's range | 8.35 - 8.60 |
| Contract range | N/A |
| Volume | |
| Open interest | 183 |
ZacksWhy Is Apellis Pharmaceuticals (APLS) Down 1.9% Since Last Earnings Report?
Apellis Pharmaceuticals (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GlobeNewswireApellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
WALTHAM, Mass., June 05, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference on Wednesday, June 12, 2024, at 4:00 p.m. ET. The live conference webcast will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for approximately 90 days following the event. Abou
ZacksApellis (APLS) Posts Upbeat One-Year Kidney Diseases Study Data
Apellis (APLS) reports positive one-year data from the mid-stage study evaluating systemic pegcetacoplan to treat two rare and debilitating kidney diseases.
